Efficacy and safety of adalimumab in ankylosing spondylitis
Aziza Mounach, Abdellah El MaghraouiRheumatology Department, Military Hospital Mohammed V, Rabat, MoroccoAbstract: Ankylosing spondylitis (AS) is the most common and most severe subtype of spondyloarthritis. It also may be an outcome of any of the other spondyloarthritis subtypes. AS preferentially...
Guardado en:
Autores principales: | Mounach A, El Maghraoui A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4431ef900ec048c58a43f06f6e1098e7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Management of ankylosing spondylitis with infliximab
por: Éric Toussirot, et al.
Publicado: (2009) -
The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases
por: Jeffrey R. Curtis, et al.
Publicado: (2021) -
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
por: Fabrizio Cantini, et al.
Publicado: (2009) -
Long-term use of adalimumab in the treatment of rheumatic diseases
por: Charalampos Papagoras, et al.
Publicado: (2009) -
Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca G, et al.
Publicado: (2013)